8-K: Global Medical REIT Announces Fourth Quarter and Full Year 2024 Financial Results, Joint Venture with Heitman, and 2025 Guidance

Global Medical REIT reports its Q4 and full year 2024 financial results, highlighting acquisitions, a joint venture with Heitman, and provides AFFO guidance for 2025.

Summary

• Global Medical REIT (GMRE) announced its financial results for the three and twelve months ended December 31, 2024.
• The company acquired $80.3 million of single-tenant triple-net medical real estate in 2024.
• GMRE announced a joint venture with Heitman and declared first quarter 2025 common and preferred dividends.
• The company is introducing full year 2025 AFFO per share and unit guidance of $0.89 to $0.93.
• Net income attributable to common stockholders for Q4 2024 was $1.4 million, or $0.02 per diluted share, compared to a net loss of $0.8 million, or $0.01 per diluted share, in Q4 2023.
• FFO for Q4 2024 was $11.1 million, or $0.15 per share and unit, compared to $13.3 million, or $0.19 per share and unit, in Q4 2023.
• AFFO for Q4 2024 was $15.8 million, or $0.22 per share and unit, compared to $15.9 million, or $0.23 per share and unit, in Q4 2023.
• For the full year 2024, net income attributable to common stockholders was $0.8 million, or $0.01 per diluted share, compared to $14.8 million, or $0.23 per diluted share, in 2023.
• Full year 2024 FFO was $53.6 million, or $0.75 per share and unit, compared to $58.4 million, or $0.83 per share and unit, in 2023.
• Full year 2024 AFFO was $63.4 million, or $0.89 per share and unit, compared to $64.3 million, or $0.91 per share and unit, in 2023.
• The company completed the acquisition of a 15-property portfolio for $80.3 million with an annualized base rent of $6.4 million.
• Seven dispositions were completed in 2024, generating $60.7 million in gross proceeds and a $4.2 million gain.
• Portfolio leased occupancy was 96.4% at December 31, 2024.
• The company raised $12 million through the issuance of 1.2 million shares of common stock at an average price of $9.95 per share.
• As of December 31, 2024, total debt outstanding was $646.1 million, and leverage was 44.8%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company highlights acquisitions and a joint venture, the decrease in FFO and AFFO, along with CEO transition costs and an impairment charge, temper the overall outlook. The 2025 guidance provides some optimism, but the risks associated with assumptions and market conditions keep the sentiment from being overly positive.

Positives

• Net income attributable to common stockholders increased in Q4 2024 compared to Q4 2023.
• The company successfully executed acquisitions and dispositions, optimizing its portfolio.
• The joint venture with Heitman provides additional growth opportunities.
• High portfolio occupancy rate of 96.4% indicates strong demand for the company's properties.
• The company is paying regular dividends to both common and preferred stockholders.
• The company improved its overall GRESB score to 57 for 2024, reflecting a commitment to sustainability.

Negatives

• FFO and AFFO decreased for both Q4 and the full year 2024 compared to the prior year periods.
• Net income attributable to common stockholders decreased for the full year 2024 compared to 2023.
• The company incurred $3.2 million in costs related to CEO severance and transition.
• A non-cash impairment charge of $1.7 million was recorded on one property.
• Prospect Medical Group's bankruptcy filing poses a potential risk, representing 0.8% of total annualized base rent.

Risks

• The company's obligation to close the remainder of the five-property portfolio acquisition is subject to customary terms and conditions, with no assurance of timely completion.
• Prospect Medical Group's bankruptcy could impact rental income if leases are rejected.
• The company's 2025 guidance is based on assumptions that are subject to change and outside of the company's control.
• Climate change poses both physical and transitional risks to the company's properties.
• The company's debt carries a weighted average remaining term of 2.0 years, indicating potential refinancing risk in the near future.

Future Outlook

The company is introducing its full year 2025 AFFO per share and unit guidance of $0.89 to $0.93, based on certain assumptions including no additional acquisitions or dispositions other than those already completed or announced, and no additional equity or debt issuances other than normal course Revolver borrowing/repayments.

Management Comments

• Jeffrey M. Busch, Chairman, Chief Executive Officer and President stated, 'During the year we maintained our disciplined acquisition approach for quality healthcare real estate by closing on a 15-property, single-tenant triple-net portfolio for $80.3 million at a cap rate of 8.0% and entered into a purchase agreement to acquire a five-property, $69.6 million portfolio at a cap rate of 9.0%.'
• Jeffrey M. Busch also stated, 'We believe the joint venture will provide additional opportunities to acquire assets and earn ancillary fee income with a strong capital partner.'
• Jeffrey M. Busch also stated, 'In summary, we believe our 2024 acquisitions and new joint venture are indicative of our ability to identify and execute on growth opportunities.'

Industry Context

The announcement reflects the ongoing trend of REITs focusing on healthcare properties due to the sector's stability and growing demand. The joint venture with Heitman, a large real estate investment firm, indicates a strategic move to leverage capital and expertise for further expansion in the medical real estate market.

Comparison to Industry Standards

• GMRE's portfolio occupancy of 96.4% is strong, generally in line with industry averages for medical REITs, which typically range from 93% to 98%.
• The weighted average lease term of 5.6 years is fairly typical for net-lease REITs, providing a reasonable level of stability.
• The rent coverage ratio of 4.5x is healthy, indicating that tenants are generally able to comfortably cover their rent obligations.
• Comparing GMRE to peers like Physicians Realty Trust (DOC) or Healthcare Trust of America (HTA), GMRE's leverage ratio of 44.8% is within a reasonable range for REITs, but it's important to monitor this metric closely.
• The AFFO guidance of $0.89 to $0.93 is a key metric to watch, and investors will compare this to the performance and guidance of similar REITs to assess GMRE's relative value.

Management Changes

Corporate Governance

Legal Proceedings

• Prospect Medical Group filed for Chapter 11 bankruptcy reorganization.

Stakeholder Impact

• Shareholders will be impacted by the dividend payments and the company's overall financial performance.
• Employees will be affected by the CEO transition and any potential changes in company strategy.
• Tenants may be impacted by any changes in property management or ownership resulting from acquisitions or dispositions.
• The community benefits from the company's commitment to sustainability and energy efficiency.

Next Steps

• Complete the acquisition of the remaining two properties in the five-property portfolio during the second quarter of 2025.
• Monitor Prospect Medical Group's bankruptcy proceedings and potential impact on rental income.
• Execute the CEO succession plan and appoint a new Chief Executive Officer.
• Hold the 2025 Annual Stockholders Meeting on May 14, 2025.
• Continue to assess and mitigate climate-related risks to the company's properties.

Key Dates